INDICATION

EVENITY™ is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Read More

available osteoporosis therapy. The anabolic effect of EVENITY™ wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY™ use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered. Close

EVENITY™ is the first and only bone builder that works differently with a dual effect1-3

EVENITY™ works with the body's natural ability to increase bone formation and, to a lesser extent, decrease bone resorption1

Mechanism of action representations are for illustrative purposes only and are not meant to imply clinical efficacy.

EVENITY™ is a humanized monoclonal antibody that binds and inhibits sclerostin, a regulatory factor in bone metabolism1

WATCH TO LEARN MORE

IMPORTANT SAFETY INFORMATION
IMPORTANT SAFETY INFORMATION

POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH
EVENITY™ may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY™ should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY™ should be discontinued.

References: 1. EVENITY™ (romosozumab-aqqg) prescribing information, Amgen. 2. Forteo® (teriparatide) prescribing information, Eli Lilly and Company. 3. Tymlos® (abaloparatide) prescribing information, Radius Health, Inc.